MY ACCOUNT | NEWSLETTER |

BVDV infection: Effect on reproductive performance and milk yield in dairy herds

BVDV infection affected reproductive performance


The impact of an outbreak of bovine viral diarrhea (BVD) on reproductive performance and milk production was investigated in 28 Spanish dairy herds using an observational study design. Mean calving to conception interval (CCI), mean number of inseminations per conception (AI/P) and mean daily milk yield were recorded from herds affected by outbreaks. Infection was confirmed by evidence of viral transmission to young stock (heifers 9-24 months) and persistently infected animals, after previous BVD-free status. Fifteen herds did not use vaccines (G1) whereas the remaining 13 received modified live BVD virus (BVDV) vaccines (G2). In G1 herds, a significant increase in CCI (13.8 days; 95% CI, 0.4-27.3 days; P = 0.050) was observed during the BVD outbreak compared to the year before the outbreak. In G2 herds, there was a not a significant increase in CCI (3.0 days; 95% CI, -1.2-7.2 days; P = 0.558).

Changes in AI/P between periods were not significant in any of the herds. In G1 herds, there was an increase of 0.09 units (P > 0.05) during the outbreak, whereas in G2 herds, AI/P decreased 0.08 units (P > 0.05). Compared to milk production in the year before the BVD outbreak, there was no significant change in G1 herds throughout the study period (P > 0.05), but there were significant increases in G2 herds over the study period (P1-P2, 1.4 kg/day increase, P = 0.019; P1-P3, 2.0 kg/day increase, P = 0.007). These results indicate that BVDV infection affected reproductive performance, which is critical in maintaining dairy herd profitability.

“Bovine viral diarrhea virus (BVDV) infection: Effect on reproductive performance and milk yield in dairy herds”. Ignacio Arnaiz, et al. Vet J. 2021 Sep 16;277:105747.  doi: 10.1016/j.tvjl.2021.105747.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Idiopathic Hypercalcemia in Cats

Like0
Dislike1

Unified Information Devices, Inc.

Like0
Dislike1

Effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats.

Like0
Dislike1

The polysaccharide Pullulan improves the initial steps of allergen-specific immunotherapy in dogs.

Like0
Dislike1

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top